200 related articles for article (PubMed ID: 23174090)
21. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
22. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
Otte C; Hinkelmann K; Moritz S; Yassouridis A; Jahn H; Wiedemann K; Kellner M
J Psychiatr Res; 2010 Apr; 44(6):339-46. PubMed ID: 19909979
[TBL] [Abstract][Full Text] [Related]
23. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.
Schindler F; Anghelescu IG
Int Clin Psychopharmacol; 2007 May; 22(3):179-82. PubMed ID: 17414745
[TBL] [Abstract][Full Text] [Related]
24. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
Goff DC; Herz L; Posever T; Shih V; Tsai G; Henderson DC; Freudenreich O; Evins AE; Yovel I; Zhang H; Schoenfeld D
Psychopharmacology (Berl); 2005 Apr; 179(1):144-50. PubMed ID: 15502972
[TBL] [Abstract][Full Text] [Related]
25. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
26. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
Kasper S; Volz HP; Möller HJ; Dienel A; Kieser M
Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
[TBL] [Abstract][Full Text] [Related]
27. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial.
Pope HG; Cohane GH; Kanayama G; Siegel AJ; Hudson JI
Am J Psychiatry; 2003 Jan; 160(1):105-11. PubMed ID: 12505808
[TBL] [Abstract][Full Text] [Related]
28. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
30. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study.
Bergman J; Miodownik C; Bersudsky Y; Sokolik S; Lerner PP; Kreinin A; Polakiewicz J; Lerner V
Clin Neuropharmacol; 2013; 36(3):73-7. PubMed ID: 23673908
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder.
Montgomery SA; Feighner JP; Sverdlov L; Shrivastava RK; Cunningham LA; Kiev A; Hlavka J; Tonelli G
Int J Neuropsychopharmacol; 2006 Oct; 9(5):517-28. PubMed ID: 16259645
[TBL] [Abstract][Full Text] [Related]
32. Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Yu JJ; Pei LB; Zhang Y; Wen ZY; Yang JL
J Clin Psychopharmacol; 2015 Aug; 35(4):406-10. PubMed ID: 26066335
[TBL] [Abstract][Full Text] [Related]
33. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
35. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
Kramer MS; Winokur A; Kelsey J; Preskorn SH; Rothschild AJ; Snavely D; Ghosh K; Ball WA; Reines SA; Munjack D; Apter JT; Cunningham L; Kling M; Bari M; Getson A; Lee Y
Neuropsychopharmacology; 2004 Feb; 29(2):385-92. PubMed ID: 14666114
[TBL] [Abstract][Full Text] [Related]
36. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
[TBL] [Abstract][Full Text] [Related]
37. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
38. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
39. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
Pancheri P; Scapicchio P; Chiaie RD
Int J Neuropsychopharmacol; 2002 Dec; 5(4):287-94. PubMed ID: 12466028
[TBL] [Abstract][Full Text] [Related]
40. Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder.
Heresco-Levy U; Vass A; Bloch B; Wolosker H; Dumin E; Balan L; Deutsch L; Kremer I
Int J Neuropsychopharmacol; 2009 Oct; 12(9):1275-82. PubMed ID: 19366490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]